Clinical Trial Update: Investigating the Clinical Consequences of Flutemetamol-PET-scanning [Phase 3]

View source ↗

Summary

Phase 3 study investigating clinical consequences of Flutemetamol-PET scanning was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease
• Cognitive Impairment
• Dementia

Drugs mentioned

• Flutemetamol-PET

Snippet

Sponsor: University of Zurich | Conditions: Mild Cognitive Impairment, Alzheimer's Disease | Phase 3 | Status: TERMINATED